中国生物制药：泰德制药创新贴剂崛起年复合增长率 5%

和讯网2025-04-29

【4月29日，中国生物制药核心企业北京泰德制药自主研发的妥洛特罗贴剂已实现全渠道供应】作为国产首款妥洛特罗贴剂，北京泰德以创新治疗方案借助互联网重塑慢性呼吸系统疾病治疗格局。全球透皮给药市场在老龄化加剧与慢性病负担加重的双重驱动下，正以5%的年复合增长率扩容。我国慢性呼吸系统疾病患者较多，传统呼吸疾病治疗有技术瓶颈，北京泰德制药的妥洛特罗贴剂采用缓释技术避免了这些瓶颈，提升药物利用率，降低哮喘患者...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2531241806?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-29 12:14","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2531241806","market":"hk","top_or_hot":-1,"title":"中国生物制药：泰德制药创新贴剂崛起 年复合增长率 5%","media":"和讯网","content":"<div>\n<p>【4月29日，中国生物制药核心企业北京泰德制药自主研发的妥洛特罗贴剂已实现全渠道供应】作为国产首款妥洛特罗贴剂，北京泰德以创新治疗方案借助互联网重塑慢性呼吸系统疾病治疗格局。全球透皮给药市场在老龄化加剧与慢性病负担加重的双重驱动下，正以5%的年复合增长率扩容。我国慢性呼吸系统疾病患者较多，传统呼吸疾病治疗有技术瓶颈，北京泰德制药的妥洛特罗贴剂采用缓释技术避免了这些瓶颈，提升药物利用率，降低哮喘患者...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429121735a46b725e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国生物制药：泰德制药创新贴剂崛起 年复合增长率 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国生物制药：泰德制药创新贴剂崛起 年复合增长率 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-29 12:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429121735a46b725e&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【4月29日，中国生物制药核心企业北京泰德制药自主研发的妥洛特罗贴剂已实现全渠道供应】作为国产首款妥洛特罗贴剂，北京泰德以创新治疗方案借助互联网重塑慢性呼吸系统疾病治疗格局。全球透皮给药市场在老龄化加剧与慢性病负担加重的双重驱动下，正以5%的年复合增长率扩容。我国慢性呼吸系统疾病患者较多，传统呼吸疾病治疗有技术瓶颈，北京泰德制药的妥洛特罗贴剂采用缓释技术避免了这些瓶颈，提升药物利用率，降低哮喘患者...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429121735a46b725e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429121735a46b725e&s=b","article_id":"2531241806","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429121735a46b725e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2531241806","pubTimestamp":1745900072,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"作为国产首款妥洛特罗贴剂，北京泰德以创新治疗方案借助互联网重塑慢性呼吸系统疾病治疗格局。全球透皮给药市场在老龄化加剧与慢性病负担加重的双重驱动下，正以5%的年复合增长率扩容。我国慢性呼吸系统疾病患者较多，传统呼吸疾病治疗有技术瓶颈，北京泰德制药的妥洛特罗贴剂采用缓释技术避免了这些瓶颈，提升药物利用率，降低哮喘患者“晨降”难题。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01477":"欧康维视生物-B","BK1589":"北水核心资产","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","BK1515":"抗疫概念","BK1574":"生物医药B类股","01177":"中国生物制药"},"translate_title":"China Biopharmaceuticals: The rise of Tide Pharmaceutical's innovative patches has a compound annual growth rate of 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1,"01477":1},"content_text":"【4月29日，中国生物制药核心企业北京泰德制药自主研发的妥洛特罗贴剂已实现全渠道供应】作为国产首款妥洛特罗贴剂，北京泰德以创新治疗方案借助互联网重塑慢性呼吸系统疾病治疗格局。全球透皮给药市场在老龄化加剧与慢性病负担加重的双重驱动下，正以5%的年复合增长率扩容。我国慢性呼吸系统疾病患者较多，传统呼吸疾病治疗有技术瓶颈，北京泰德制药的妥洛特罗贴剂采用缓释技术避免了这些瓶颈，提升药物利用率，降低哮喘患者“晨降”难题。泰德制药副总裁赵焰平称，德瑞妥适用人群正加快下探至9岁以下儿童，预计下半年获批后将打开儿科市场。透皮给药系统是中国医药产业转型升级的重要突破口，2023年全球医用透皮贴剂市场规模为78.8亿美元，预计到2029年将达103.3亿美元。因工艺复杂等原因，长期以来北美和欧洲是透皮贴剂主要市场，国内企业面临诸多困难，泰德制药构建起四大技术平台，打通全产业链体系。透皮给药技术正成为慢性病管理革新力量，北京泰德已推动5款贴剂产品获批上市，其创新技术平台已延伸至神经退行性疾病领域。依托生产基地及电商平台服务模式，北京泰德正加速将实验室成果转化为临床价值。(责任编辑：张晓波)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2531241806","isCrawlerRequest":true}

中国生物制药：泰德制药创新贴剂崛起 年复合增长率 5%

精彩评论

中国生物制药：泰德制药创新贴剂崛起年复合增长率 5%